Glutamatergic Modulation as a Treatment for Depressive Symptoms Among

Status Recruiting

Clinical Trial Summary

Post-acute sequelae of SARS-CoV2 (PASC), colloquially known as "long-COVID," is thought to affect between 10-30% of all COVID-19 survivors. Patients with PASC also report worsening behavioral health symptoms over time that include new-onset depression, anxiety, and even suicidal behavior. The purpose of this randomized, double-blind, controlled trial is to test the efficacy of a glutamate modulator among PASC patients suffering from new-onset or worsening of depressive symptoms.

Clinical Trial Description

While PASC symptoms have been identified in nearly every organ system, the most common symptoms include fatigue, cognitive and attention deficits (known as 'brain fog'), shortness of breath, and post-exertional malaise. New-onset depression, anxiety, and even suicidal behavior have also been reported. Symptoms of PASC can exhibit daily variation; additionally PASC frequently demonstrates a relapsing and remitting course. This is mitigated by cognitive and emotional stress, physical exertion, diet, and alcohol consumption; therefore, measuring treatment response and the course of illness over time can be challenging. While there are many ongoing trials evaluating a variety of treatments for PASC, no clear treatment has emerged; additionally, there are no published data on psychotropic medications alleviating the inflammatory response and psychiatric symptoms in PASC. Alterations in the transmission between neurons of a neurotransmitter called glutamate are an important target of pharmacotherapy for PASC. Glutamate modulators have demonstrated promise in improving depressive symptoms and suicidality and can improve cognitive functioning among patients with these symptoms. The study team has recently developed a novel design that integrates a clinical trial involving serial infusions. The current trial will evaluate the effect of a sub-anesthetic infusion on individuals with PASC and depressive symptoms who complete a randomized, double-blind, placebo-controlled pilot study conducted over 5 weeks using a cross-over and counterbalanced design. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05690503
Study type	Interventional
Source	New York State Psychiatric Institute
Contact	Saleena Subaiya, MD
Phone	646-774-6117
Email	saleena.subaiya@nyspi.columbia.edu
Status	Recruiting
Phase	Phase 2
Start date	March 20, 2023
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02909387` - Adapting Project UPLIFT for Blacks in Georgia	N/A
Completed	`NCT05702086` - Making SPARX Fly in Nunavut: Pilot Testing an E-intervention for Boosting Resilience Against Youth Depression	N/A
Terminated	`NCT04921332` - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD	N/A
Completed	`NCT03535805` - Transdiagnostic, Cognitive and Behavioral Intervention for in School-aged Children With Emotional and Behavioral Disturbances	N/A
Recruiting	`NCT06100146` - Effectiveness of Fortification With Folic Acid and Vitamin B12 Among Teenage Girls	N/A
Recruiting	`NCT03272230` - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System	N/A
Completed	`NCT03514355` - MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms	N/A
Completed	`NCT05376397` - Testing THRIVE 365 for Black Sexual Minority Men (On The Daily)	N/A
Terminated	`NCT04367636` - The Effects of Attention Training on Emotion Regulation and Stress Related Complaints During COVID-19	N/A
Completed	`NCT04403126` - To Increase Psychological Well-being by the Implementation of Forgiveness Education	N/A
Recruiting	`NCT05078424` - Cognitive Behavioural Therapy for Youths With Depressive and Anxiety Symptoms in Hong Kong	N/A
Recruiting	`NCT06053775` - Non-Invasive Brain Stimulation and Cognitive Training for Depressive Symptomatology Related to Breast Cancer (ONCODEP)	N/A
Active, not recruiting	`NCT04084795` - Augmentation of EMDR With tDCS in the Treatment of Fibromyalgia	N/A
Recruiting	`NCT04082052` - Evaluating and Predicting Response to a Single Session Intervention for Self-Dislike	N/A
Completed	`NCT04011540` - Digital Data in Mental Health Therapy	N/A
Not yet recruiting	`NCT06413849` - Telephone-coached "Graphic Narrative" Bibliotherapy for Dementia Caregivers	N/A
Not yet recruiting	`NCT03659591` - Triple Aim Psychotherapy: Aimed at Improving Patient Experience, Population Health, and Cost	N/A
Not yet recruiting	`NCT02133170` - "Mindfulness vs Psychoeducation in Bipolar Disorder"	N/A
Completed	`NCT02314390` - Group- Versus Individual-Mindfulness-Based Cognitive Therapy: a Randomized Trial	N/A
Completed	`NCT01628016` - The Effect of Attention Bias Modification Training on Reducing Depressive Symptoms	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms